Skip to main content
Bruce Scharschmidt, MD, Gastroenterology, San Francisco, CA

BruceFScharschmidtMD

Gastroenterology • San Francisco, CA

Hepatology & Liver Transplantation

Senior VP & Chief Medical Officer, Hyperion Therapeutics

Join to view full profile

Dr. Scharschmidt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Scharschmidt's full profile

Already have an account?

Summary

  • Dr. Scharschmidt was most recently Sr. Vice President and Chief Medical & Development Officer at Hyperion Therapeutics, where he oversaw the development of glycerol phenylbutyrate (GPB, RAVICTI®), approved for treatment of urea cycle disorders in the US, Europe and Canada and the successful phase 2 trial of GPB for hepatic encephalopathy. He was inventor/co-inventor on Hyperion’s intellectual property, a member of Hyperion’s road show team leading to its 2012 IPO, 2013 secondary offering and May 2015 sale to Horizon Pharma. Bruce previously held VP positions at Novartis and Chiron, where he was involved in the development of multiple vaccines and therapeutics now approved in the US and/or Europe. Prior to joining industry, Bruce was Professor of Medicine and Chief of Gastroenterology at Univ. of CA, San Francisco (UCSF), where he was an NIH-funded investigator for two decades and helped launch the UCSF liver transplant program. Bruce is currently Independent Director, co-founder and/or consultant to several biotechnology companies.
    Bruce is author of over 200 research and review articles and multiple patents as well as of several children’s books (visit brucescharschmidt.com). He served as Editor of Sleisenger & Fordtran’s Textbook of Gastroenterology, Assoc. Editor of Gastroenterology, Editor-in-Chief of the Journal of Clinical Investigation, President of the American Society for Clinical Investigation and as mentor to colleagues in academia and industry. He is Board Certified in Internal Medicine and Gastroenterology, was a member of the National Board of Directors of the American Liver Foundation from 2005-2013 and is a member of the President’s Council Executive Committee for UCSF’s J. David Gladstone Institute. Bruce served on the External Advisory Board for the Northwestern University Feinberg School of Medicine’s (NUFSM) Clinical and Translational Science Program (NUCATS)(2008-21), is Past President of NUFSM’s Medical Association Alumni Board, was named NUFS

Education & Training

  • Northwestern University The Feinberg School of Medicine
    Northwestern University The Feinberg School of MedicineClass of 1970

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1973 - 2014

Awards, Honors, & Recognition

  • Editor, Journal of Clinical Investigation American Society for Clinical Investigation, 1987-1992
  • Elected Member The American Society for Clinical Investigation, 1982

Clinical Trials

Publications & Presentations

PubMed

Grant Support

  • Core--Molecular Biology LaboratoryNational Institute Of Diabetes And Digestive And Kidney Diseases1996–2001
  • Mechanisms Of Canalicular Bile FormationNational Institute Of Diabetes And Digestive And Kidney Diseases1986–1998
  • Pilot Study--Electrophysiological Study Of Cultured RAT HepatocytesNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985
  • Mechanisms Of Canalicular Bile FormationNat Inst Of Arthritis, Diabetes, Digestive &Kidney Diseases1985

Dr. Bruce Scharschmidt, Dr. Bruce Scharschmidt, MD, Dr. B Scharschmidt, Dr. Bruce F Scharschmidt